FLT1 and peripheral arterial disease: Based on these data, we questioned whether VEGFR1 activation achieved by VEGF165b inhibition has the ability to induce ischemic angiogenesis even when VEGFR2-eNOS-NO signaling is impaired e.g., diabetic-PAD [17,18].